Balyasny Asset Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Balyasny Asset Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-53,091	Closed	-$6.63M	–	3610
2025 Q4	$6.47M	Sell	53,091 -50,384	-49%	-$5.78M	0.01%	1262
2025 Q3	$10.4M	Sell	103,475 -113,932	-52%	-$10.3M	0.01%	1039
2025 Q2	$18M	Sell	217,407 -60,598	-22%	-$4.83M	0.03%	708
2025 Q1	$22.5M	Buy	278,005 +81,631	+42%	+$7.3M	0.04%	552
2024 Q4	$17.7M	Buy	196,374 +91,538	+87%	+$8.87M	0.03%	722
2024 Q3	$10.4M	Sell	104,836 -139,104	-57%	-$13.7M	0.02%	929
2024 Q2	$22.6M	Buy	243,940 +85,112	+54%	+$7.63M	0.04%	562
2024 Q1	$15.1M	Sell	158,828 -14,010	-8%	-$1.3M	0.03%	758
2023 Q4	$15.4M	Sell	172,838 -10,011	-5%	-$743K	0.03%	701
2023 Q3	$13.4M	Buy	182,849 +176,260	+2,675%	+$14.1M	0.03%	731
2023 Q2	$548K	Sell	6,589 -44,949	-87%	-$3.76M	﹤0.01%	1825
2023 Q1	$3.93M	Buy	+51,538	New	+$4.28M	0.01%	1176
2022 Q4	–	Sell	-27,196	Closed	-$2.2M	–	3289
2022 Q3	$2.16M	Sell	27,196 -67,102	-71%	-$5.66M	0.01%	1453
2022 Q2	$7M	Buy	94,298 +56,482	+149%	+$4.24M	0.02%	800
2022 Q1	$3.4M	Sell	37,816 -20,192	-35%	-$1.86M	0.01%	1119
2021 Q4	$6.5M	Buy	+58,008	New	+$7M	0.02%	769
2019 Q4	–	Sell	-750,000	Closed	-$57.2M	–	1539
2019 Q3	$57.2M	Buy	+750,000	New	+$62.3M	0.39%	47
2018 Q1	–	Sell	-219,000	Closed	-$18.6M	–	2363
2017 Q4	$18.6M	Buy	+219,000	New	+$18.3M	0.06%	430
2015 Q3	–	Sell	-33,000	Closed	-$2.77M	–	1409
2015 Q2	$2.77M	Buy	+33,000	New	+$2.57M	0.02%	703

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Balyasny Asset Management's XBI Position: Q1 2026 in Review

Balyasny Asset Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2026, closing a stake of 53,091 shares — an estimated $6.63M sold.

Balyasny Asset Management first reported a position in XBI in Q2 2015 and held it in 19 quarters. The position peaked at $57.2M in Q3 2019. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Balyasny Asset Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2026 after selling out during the quarter.
Balyasny Asset Management sold 53,091 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $6.63M.
Balyasny Asset Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2015 and held it in 19 quarters.
Balyasny Asset Management's State Street SPDR S&P Biotech ETF position peaked at $57.2M in Q3 2019.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.